Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177lu-lilotomab satetraxetan + lilotomab
- Development stage
- Unknown
- Lead developer
- Nordic Nanovector
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177lu-lilotomab satetraxetan + lilotomab is a combination therapy consisting of a radioimmunoconjugate (^177Lu-lilotomab satetraxetan), which is a humanized monoclonal antibody (lilotomab) targeting CD37 on B cells, labeled with the beta-emitting radionuclide lutetium-177 through the chelator satetraxetan, plus an additional non-radioactive dose of lilotomab to improve biodistribution and reduce hematologic toxicity. The therapy is developed for the treatment of relapsed or refractory indolent non-Hodgkin B-cell lymphoma, especially follicular lymphoma, and is administered as a single dose in combination after pre-treatment with rituximab. The mechanism combines antibody-mediated targeting of CD37 with beta-radiation-induced cytotoxicity, selectively destroying malignant B cells while sparing most surrounding tissue. Developed by Nordic Nanovector, this regimen is under investigation in clinical trials, typically with lilotomab "predose" prior to administration of ^177Lu-lilotomab satetraxetan to improve tumor targeting and minimize off-target effects[1][2].
- Brand names
- betalutin
- Other names
- lutetium 177lu-lilotomab satetraxetan + lilotomab
02
Targets
CD37
Beyond the preview
Go deeper on 177lu-lilotomab satetraxetan + lilotomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177lu-lilotomab satetraxetan + lilotomab.